BioNTech SE clinical trial pipeline

COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

Trial completed

Also in this update: Primary completion date changed from estimate of Jul 31, 2026 to Sep 22, 2026

BioNTech SE·Phase 3· NCT07300839· Registry history of NCT07300839 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026

BNT327, an Investigational Therapy in Combination With…BNT327, an Investigational Therapy in Combination With Chemotherapy · Untreated Small-cell Lung Cancer

Primary completion pushed from Dec 2028 to Apr 2029

Also in this update: Study completion pushed from Mar 2029 to Jul 2029

BioNTech SE·Phase 3· NCT06712355· Registry history of NCT06712355 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026

Fern-EC-01 · Anti-cancer Effects of an Investigational Therapy or…Fern-EC-01 · Anti-cancer Effects of an Investigational Therapy or Chemotherapy · Recurring Uterine Cancer

Trial sites expanded: 191 → 206 locations

BioNTech SE·Phase 3· NCT06340568· Registry history of NCT06340568 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026

BNT324 Versus Docetaxel in Metastatic Castration-resistant…BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Trial sites expanded: 33 → 52 locations

BioNTech SE·Phase 3· NCT07365995· Registry history of NCT07365995 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026

AHEAD-MERIT · Therapeutic Effects of BNT113 in Combination With…AHEAD-MERIT · Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone · a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Trial sites reduced: 142 → 138 locations

And 1 more change in the last 30 days

BioNTech SE·Phase 2/3· NCT04534205· Registry history of NCT04534205 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026

Look at the Safety and Immune Responses of the RNA-based Vaccine…Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 · or Without HIV

Trial sites expanded: 1 → 4 locations

BioNTech SE·Phase 1· NCT07698600· Registry history of NCT07698600 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026

ROSETTA Breast-01 · Effects and Safety of Pumitamig…ROSETTA Breast-01 · Effects and Safety of Pumitamig · Triple-Negative Breast Cancer

Trial sites expanded: 202 → 212 locations

BioNTech SE·Phase 3· NCT07173751· Registry history of NCT07173751 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026

BNT327 in Combination With Chemotherapy and Other Investigational…BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Trial sites expanded: 262 → 365 locations

BioNTech SE·Phase 2/3· NCT06712316· Registry history of NCT06712316 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026

RO7198457 Versus Watchful Waiting · ctDNA-positive, Resected…RO7198457 Versus Watchful Waiting · ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Study completion moved earlier from Aug 2030 to Nov 2026

BioNTech SE·Phase 2· NCT04486378· Registry history of NCT04486378 on ClinicalTrials.gov (opens the registry)

Oct 7, 2026